AP136A - Substituted:- 1,3-oxathiolanes with antiviral properties. - Google Patents

Substituted:- 1,3-oxathiolanes with antiviral properties. Download PDF

Info

Publication number: AP136A
Authority: AP; ARIPO
Prior art keywords: formula; compound; group; oxathiolane; hydroxymethyl
Prior art date: 1989-02-08

Application number

APAP/P/1990/000163A

Other languages

English (en)

Other versions

AP9000163A0 (en

Inventor

BELLEAY, (DECEASED) Bernard

Belleau, (Executor Of Estate) Pierette

Nghe Nguyen-Ba

Original Assignee

Iaf Biochem Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-02-08

Filing date

1990-02-08

Publication date

1991-08-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25678044&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP136(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1990-02-08 Application filed by Iaf Biochem Int filed Critical Iaf Biochem Int

1990-04-30 Publication of AP9000163A0 publication Critical patent/AP9000163A0/xx

1991-08-05 Application granted granted Critical

1991-08-05 Publication of AP136A publication Critical patent/AP136A/en

1992-12-21 Priority claimed from CA002152269A external-priority patent/CA2152269C/en

Links

230000000840 anti-viral effect Effects 0.000 title description 6
150000001875 compounds Chemical class 0.000 claims abstract description 103
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 27
238000000034 method Methods 0.000 claims abstract description 26
239000001257 hydrogen Substances 0.000 claims abstract description 18
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims abstract description 10
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 10
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims abstract description 9
239000000203 mixture Substances 0.000 claims description 59
125000003118 aryl group Chemical group 0.000 claims description 27
-1 cyano, carboxy, ethoxycarbonyl Chemical group 0.000 claims description 17
SFLGIMGLWCVAHP-UHFFFAOYSA-N 5h-oxathiole Chemical compound C1OSC=C1 SFLGIMGLWCVAHP-UHFFFAOYSA-N 0.000 claims description 15
238000006243 chemical reaction Methods 0.000 claims description 15
WJJSZTJGFCFNKI-UHFFFAOYSA-N 1,3-oxathiolane Chemical compound C1CSCO1 WJJSZTJGFCFNKI-UHFFFAOYSA-N 0.000 claims description 14
229920006395 saturated elastomer Polymers 0.000 claims description 13
125000000217 alkyl group Chemical group 0.000 claims description 12
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 11
230000008569 process Effects 0.000 claims description 11
238000011282 treatment Methods 0.000 claims description 11
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 10
229910052794 bromium Inorganic materials 0.000 claims description 10
239000000460 chlorine Substances 0.000 claims description 10
239000003814 drug Substances 0.000 claims description 10
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 9
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 9
229910052801 chlorine Inorganic materials 0.000 claims description 9
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 7
125000002252 acyl group Chemical group 0.000 claims description 7
239000011737 fluorine Substances 0.000 claims description 7
229910052731 fluorine Inorganic materials 0.000 claims description 7
IGFXRKMLLMBKSA-UHFFFAOYSA-N purine Chemical compound N1=C[N]C2=NC=NC2=C1 IGFXRKMLLMBKSA-UHFFFAOYSA-N 0.000 claims description 7
125000006239 protecting group Chemical group 0.000 claims description 6
229940124597 therapeutic agent Drugs 0.000 claims description 6
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 5
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 4
229910052740 iodine Inorganic materials 0.000 claims description 4
239000011630 iodine Substances 0.000 claims description 4
229910052717 sulfur Inorganic materials 0.000 claims description 4
208000036142 Viral infection Diseases 0.000 claims description 3
125000001931 aliphatic group Chemical group 0.000 claims description 3
125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 3
125000004429 atom Chemical group 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 3
230000003287 optical effect Effects 0.000 claims description 3
125000004417 unsaturated alkyl group Chemical group 0.000 claims description 3
230000009385 viral infection Effects 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 2
150000002431 hydrogen Chemical class 0.000 claims 6
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
BNVOMPQTQUUYHU-RQJHMYQMSA-N 1-[(2s,5r)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidine-2,4-dione Chemical compound C1S[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 BNVOMPQTQUUYHU-RQJHMYQMSA-N 0.000 claims 1
101150052863 THY1 gene Proteins 0.000 claims 1
238000002360 preparation method Methods 0.000 abstract description 7
239000003443 antiviral agent Substances 0.000 abstract description 5
125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 abstract 1
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 46
239000000243 solution Substances 0.000 description 25
239000004480 active ingredient Substances 0.000 description 20
239000002585 base Substances 0.000 description 20
238000005481 NMR spectroscopy Methods 0.000 description 17
150000002148 esters Chemical class 0.000 description 16
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
239000000047 product Substances 0.000 description 14
150000003839 salts Chemical class 0.000 description 14
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
241000725303 Human immunodeficiency virus Species 0.000 description 13
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
239000002777 nucleoside Substances 0.000 description 12
239000002253 acid Substances 0.000 description 10
208000030507 AIDS Diseases 0.000 description 9
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
238000009472 formulation Methods 0.000 description 9
FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 9
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
239000003795 chemical substances by application Substances 0.000 description 8
239000000543 intermediate Substances 0.000 description 8
239000000843 powder Substances 0.000 description 8
239000002904 solvent Substances 0.000 description 8
235000019439 ethyl acetate Nutrition 0.000 description 7
238000010992 reflux Methods 0.000 description 7
239000007787 solid Substances 0.000 description 7
238000003786 synthesis reaction Methods 0.000 description 7
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 7
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 6
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
241000700605 Viruses Species 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
239000007788 liquid Substances 0.000 description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
125000003835 nucleoside group Chemical group 0.000 description 6
230000003389 potentiating effect Effects 0.000 description 6
239000000741 silica gel Substances 0.000 description 6
229910002027 silica gel Inorganic materials 0.000 description 6
241001430294 unidentified retrovirus Species 0.000 description 6
XKKCQTLDIPIRQD-JGVFFNPUSA-N 1-[(2r,5s)-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)CC1 XKKCQTLDIPIRQD-JGVFFNPUSA-N 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
150000001241 acetals Chemical class 0.000 description 5
230000036436 anti-hiv Effects 0.000 description 5
239000012300 argon atmosphere Substances 0.000 description 5
125000003710 aryl alkyl group Chemical group 0.000 description 5
239000000969 carrier Substances 0.000 description 5
210000004027 cell Anatomy 0.000 description 5
239000003112 inhibitor Substances 0.000 description 5
150000003833 nucleoside derivatives Chemical class 0.000 description 5
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 5
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical class O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 4
DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 4
150000007513 acids Chemical class 0.000 description 4
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
239000002775 capsule Substances 0.000 description 4
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
150000002118 epoxides Chemical class 0.000 description 4
PSLIMVZEAPALCD-UHFFFAOYSA-N ethanol;ethoxyethane Chemical compound CCO.CCOCC PSLIMVZEAPALCD-UHFFFAOYSA-N 0.000 description 4
238000001704 evaporation Methods 0.000 description 4
230000008020 evaporation Effects 0.000 description 4
239000000284 extract Substances 0.000 description 4
125000000524 functional group Chemical group 0.000 description 4
229910052736 halogen Inorganic materials 0.000 description 4
150000002367 halogens Chemical class 0.000 description 4
230000007062 hydrolysis Effects 0.000 description 4
238000006460 hydrolysis reaction Methods 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
238000001802 infusion Methods 0.000 description 4
239000012044 organic layer Substances 0.000 description 4
239000007921 spray Substances 0.000 description 4
238000003756 stirring Methods 0.000 description 4
239000000829 suppository Substances 0.000 description 4
239000000375 suspending agent Substances 0.000 description 4
239000003826 tablet Substances 0.000 description 4
FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 4
238000005160 1H NMR spectroscopy Methods 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
230000002378 acidificating effect Effects 0.000 description 3
230000000798 anti-retroviral effect Effects 0.000 description 3
239000008346 aqueous phase Substances 0.000 description 3
CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
238000007796 conventional method Methods 0.000 description 3
239000006071 cream Substances 0.000 description 3
230000000120 cytopathologic effect Effects 0.000 description 3
239000002270 dispersing agent Substances 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
239000012458 free base Substances 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
239000008101 lactose Substances 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
231100000252 nontoxic Toxicity 0.000 description 3
125000003729 nucleotide group Chemical group 0.000 description 3
OOFGXDQWDNJDIS-UHFFFAOYSA-N oxathiolane Chemical group C1COSC1 OOFGXDQWDNJDIS-UHFFFAOYSA-N 0.000 description 3
239000003755 preservative agent Substances 0.000 description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
230000010076 replication Effects 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000007858 starting material Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
229960000523 zalcitabine Drugs 0.000 description 3
SPEUIVXLLWOEMJ-UHFFFAOYSA-N 1,1-dimethoxyethane Chemical compound COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 2
WVXRAFOPTSTNLL-NKWVEPMBSA-N 2',3'-dideoxyadenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO)O1 WVXRAFOPTSTNLL-NKWVEPMBSA-N 0.000 description 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
206010001513 AIDS related complex Diseases 0.000 description 2
241000220479 Acacia Species 0.000 description 2
IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
206010061598 Immunodeficiency Diseases 0.000 description 2
208000029462 Immunodeficiency disease Diseases 0.000 description 2
102100034343 Integrase Human genes 0.000 description 2
102000000588 Interleukin-2 Human genes 0.000 description 2
108010002350 Interleukin-2 Proteins 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
239000002841 Lewis acid Substances 0.000 description 2
208000008771 Lymphadenopathy Diseases 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
206010038997 Retroviral infections Diseases 0.000 description 2
IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 2
229940124639 Selective inhibitor Drugs 0.000 description 2
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
150000001299 aldehydes Chemical class 0.000 description 2
125000003545 alkoxy group Chemical group 0.000 description 2
229910052786 argon Inorganic materials 0.000 description 2
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
230000037396 body weight Effects 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
229940104302 cytosine Drugs 0.000 description 2
238000010511 deprotection reaction Methods 0.000 description 2
229940079593 drug Drugs 0.000 description 2
230000000857 drug effect Effects 0.000 description 2
230000000694 effects Effects 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
239000012467 final product Substances 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
125000000623 heterocyclic group Chemical group 0.000 description 2
230000007813 immunodeficiency Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
150000007517 lewis acids Chemical class 0.000 description 2
239000006210 lotion Substances 0.000 description 2
208000018555 lymphatic system disease Diseases 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
239000000463 material Substances 0.000 description 2
125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
229940127073 nucleoside analogue Drugs 0.000 description 2
239000002674 ointment Substances 0.000 description 2
239000006072 paste Substances 0.000 description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
229940069328 povidone Drugs 0.000 description 2
230000002265 prevention Effects 0.000 description 2
238000011321 prophylaxis Methods 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
238000011160 research Methods 0.000 description 2
229960000329 ribavirin Drugs 0.000 description 2
HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 2
238000007493 shaping process Methods 0.000 description 2
125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 2
238000003797 solvolysis reaction Methods 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
125000001424 substituent group Chemical group 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
150000003462 sulfoxides Chemical class 0.000 description 2
239000002562 thickening agent Substances 0.000 description 2
229940104230 thymidine Drugs 0.000 description 2
229940113082 thymine Drugs 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
229940035893 uracil Drugs 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
VRYALKFFQXWPIH-RANCGNPWSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxy-2-tritiohexanal Chemical compound O=CC([3H])[C@@H](O)[C@H](O)[C@H](O)CO VRYALKFFQXWPIH-RANCGNPWSA-N 0.000 description 1
SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
JIHQDMXYYFUGFV-UHFFFAOYSA-N 1,3,5-triazine Chemical class C1=NC=NC=N1 JIHQDMXYYFUGFV-UHFFFAOYSA-N 0.000 description 1
IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
GUTQTHVYODVCQP-UHFFFAOYSA-N 2,2-diethoxyethanethiol Chemical compound CCOC(CS)OCC GUTQTHVYODVCQP-UHFFFAOYSA-N 0.000 description 1
BTOTXLJHDSNXMW-POYBYMJQSA-N 2,3-dideoxyuridine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(=O)NC(=O)C=C1 BTOTXLJHDSNXMW-POYBYMJQSA-N 0.000 description 1
SFCPXHKCMRZQAC-UHFFFAOYSA-N 2,3-dihydroxypropyl benzoate Chemical compound OCC(O)COC(=O)C1=CC=CC=C1 SFCPXHKCMRZQAC-UHFFFAOYSA-N 0.000 description 1
125000001917 2,4-dinitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1*)[N+]([O-])=O)[N+]([O-])=O 0.000 description 1
HDZZVAMISRMYHH-UHFFFAOYSA-N 2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=CC=2C(N)=NC=NC=2N1C1OC(CO)C(O)C1O HDZZVAMISRMYHH-UHFFFAOYSA-N 0.000 description 1
JRYMOPZHXMVHTA-DAGMQNCNSA-N 2-amino-7-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O JRYMOPZHXMVHTA-DAGMQNCNSA-N 0.000 description 1
OQEDEGGYERFFGP-UHFFFAOYSA-N 2-oxoethyl benzoate Chemical compound O=CCOC(=O)C1=CC=CC=C1 OQEDEGGYERFFGP-UHFFFAOYSA-N 0.000 description 1
FLJWVVUJGVNXMZ-UHFFFAOYSA-N 2-sulfanylacetaldehyde Chemical compound SCC=O FLJWVVUJGVNXMZ-UHFFFAOYSA-N 0.000 description 1
GIIGHSIIKVOWKZ-UHFFFAOYSA-N 2h-triazolo[4,5-d]pyrimidine Chemical class N1=CN=CC2=NNN=C21 GIIGHSIIKVOWKZ-UHFFFAOYSA-N 0.000 description 1
OIHIYRYYEMJNPB-UHFFFAOYSA-N 3,6-dihydrodithiine Chemical compound C1SSCC=C1 OIHIYRYYEMJNPB-UHFFFAOYSA-N 0.000 description 1
NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
OOBICGOWICFMIX-POYBYMJQSA-N 4-amino-1-[(2r,5s)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1C=C[C@@H](CO)O1 OOBICGOWICFMIX-POYBYMJQSA-N 0.000 description 1
MFEFTTYGMZOIKO-UHFFFAOYSA-N 5-azacytosine Chemical compound NC1=NC=NC(=O)N1 MFEFTTYGMZOIKO-UHFFFAOYSA-N 0.000 description 1
ZKBQDFAWXLTYKS-UHFFFAOYSA-N 6-Chloro-1H-purine Chemical compound ClC1=NC=NC2=C1NC=N2 ZKBQDFAWXLTYKS-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical group CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
108010041397 CD4 Antigens Proteins 0.000 description 1
JDVVGAQPNNXQDW-WCMLQCRESA-N Castanospermine Natural products O[C@H]1[C@@H](O)[C@H]2[C@@H](O)CCN2C[C@H]1O JDVVGAQPNNXQDW-WCMLQCRESA-N 0.000 description 1
JDVVGAQPNNXQDW-TVNFTVLESA-N Castinospermine Chemical compound C1[C@H](O)[C@@H](O)[C@H](O)[C@H]2[C@@H](O)CCN21 JDVVGAQPNNXQDW-TVNFTVLESA-N 0.000 description 1
KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
206010010071 Coma Diseases 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
102000003951 Erythropoietin Human genes 0.000 description 1
108090000394 Erythropoietin Proteins 0.000 description 1
KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
229940121672 Glycosylation inhibitor Drugs 0.000 description 1
241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
229930010555 Inosine Natural products 0.000 description 1
UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical class O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
208000007766 Kaposi sarcoma Diseases 0.000 description 1
125000002061 L-isoleucyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](C([H])([H])[H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
125000003580 L-valyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241000713869 Moloney murine leukemia virus Species 0.000 description 1
241001529936 Murinae Species 0.000 description 1
ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 1
125000003047 N-acetyl group Chemical group 0.000 description 1
206010067482 No adverse event Diseases 0.000 description 1
208000001388 Opportunistic Infections Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
206010049025 Persistent generalised lymphadenopathy Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
239000005864 Sulphur Substances 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
RZCIEJXAILMSQK-JXOAFFINSA-N TTP Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 RZCIEJXAILMSQK-JXOAFFINSA-N 0.000 description 1
102400000160 Thymopentin Human genes 0.000 description 1
101800001703 Thymopentin Proteins 0.000 description 1
229910021627 Tin(IV) chloride Inorganic materials 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
102000004357 Transferases Human genes 0.000 description 1
108090000992 Transferases Proteins 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
229960004150 aciclovir Drugs 0.000 description 1
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
239000003377 acid catalyst Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
150000001447 alkali salts Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
150000004703 alkoxides Chemical class 0.000 description 1
125000004183 alkoxy alkyl group Chemical group 0.000 description 1
125000005907 alkyl ester group Chemical group 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
239000002259 anti human immunodeficiency virus agent Substances 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
125000005160 aryl oxy alkyl group Chemical group 0.000 description 1
JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical class N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 1
UIJGNTRUPZPVNG-UHFFFAOYSA-N benzenecarbothioic s-acid Chemical compound SC(=O)C1=CC=CC=C1 UIJGNTRUPZPVNG-UHFFFAOYSA-N 0.000 description 1
150000008107 benzenesulfonic acids Chemical class 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000013060 biological fluid Substances 0.000 description 1
BFAKENXZKHGIGE-UHFFFAOYSA-N bis(2,3,5,6-tetrafluoro-4-iodophenyl)diazene Chemical compound FC1=C(C(=C(C(=C1F)I)F)F)N=NC1=C(C(=C(C(=C1F)F)I)F)F BFAKENXZKHGIGE-UHFFFAOYSA-N 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000036765 blood level Effects 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
150000001722 carbon compounds Chemical class 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
229960004424 carbon dioxide Drugs 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
238000011109 contamination Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
230000001461 cytolytic effect Effects 0.000 description 1
230000006196 deacetylation Effects 0.000 description 1
238000003381 deacetylation reaction Methods 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
239000005549 deoxyribonucleoside Substances 0.000 description 1
150000001991 dicarboxylic acids Chemical class 0.000 description 1
229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
229960002656 didanosine Drugs 0.000 description 1
125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
239000000539 dimer Substances 0.000 description 1
125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
229960002768 dipyridamole Drugs 0.000 description 1
201000010099 disease Diseases 0.000 description 1
231100000676 disease causative agent Toxicity 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000008157 edible vegetable oil Substances 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
229940105423 erythropoietin Drugs 0.000 description 1
125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000006260 foam Substances 0.000 description 1
229960005102 foscarnet Drugs 0.000 description 1
238000001640 fractional crystallisation Methods 0.000 description 1
239000012634 fragment Substances 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
229940044627 gamma-interferon Drugs 0.000 description 1
229960002963 ganciclovir Drugs 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000003349 gelling agent Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
239000008187 granular material Substances 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
229940116364 hard fat Drugs 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
239000000710 homodimer Substances 0.000 description 1
238000007327 hydrogenolysis reaction Methods 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
229960003786 inosine Drugs 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000012528 membrane Substances 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 1
HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 1
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
239000002324 mouth wash Substances 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
MRWXACSTFXYYMV-FDDDBJFASA-N nebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC=C2N=C1 MRWXACSTFXYYMV-FDDDBJFASA-N 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
239000002687 nonaqueous vehicle Substances 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
239000003921 oil Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
235000010603 pastilles Nutrition 0.000 description 1
201000003450 persistent generalized lymphadenopathy Diseases 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
235000011007 phosphoric acid Nutrition 0.000 description 1
150000003016 phosphoric acids Chemical class 0.000 description 1
230000000865 phosphorylative effect Effects 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
239000003380 propellant Substances 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
239000002212 purine nucleoside Substances 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
108010043277 recombinant soluble CD4 Proteins 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
238000012216 screening Methods 0.000 description 1
210000000582 semen Anatomy 0.000 description 1
238000000926 separation method Methods 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229940080313 sodium starch Drugs 0.000 description 1
JJICLMJFIKGAAU-UHFFFAOYSA-M sodium;2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)purin-6-olate Chemical compound [Na+].NC1=NC([O-])=C2N=CN(COC(CO)CO)C2=N1 JJICLMJFIKGAAU-UHFFFAOYSA-M 0.000 description 1
RBBWNXJFTBCLKT-UHFFFAOYSA-M sodium;ethanethioate Chemical compound [Na+].CC([S-])=O RBBWNXJFTBCLKT-UHFFFAOYSA-M 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000010186 staining Methods 0.000 description 1
229940032147 starch Drugs 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000001384 succinic acid Substances 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
238000012360 testing method Methods 0.000 description 1
125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000008719 thickening Effects 0.000 description 1
206010043554 thrombocytopenia Diseases 0.000 description 1
229940027755 thymomodulin Drugs 0.000 description 1
PSWFFKRAVBDQEG-YGQNSOCVSA-N thymopentin Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 PSWFFKRAVBDQEG-YGQNSOCVSA-N 0.000 description 1
229960004517 thymopentin Drugs 0.000 description 1
HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 1
XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
125000004665 trialkylsilyl group Chemical group 0.000 description 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1
239000001226 triphosphate Substances 0.000 description 1
235000011178 triphosphate Nutrition 0.000 description 1
UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical class OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
230000035899 viability Effects 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
239000003039 volatile agent Substances 0.000 description 1
238000005550 wet granulation Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
235000005074 zinc chloride Nutrition 0.000 description 1
239000011592 zinc chloride Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
- C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
- C07D327/04—Five-membered rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Virology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
General Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Saccharide Compounds (AREA)

APAP/P/1990/000163A 1989-02-08 1990-02-08 Substituted:- 1,3-oxathiolanes with antiviral properties. AP136A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US07/308,101 US5047407A (en)	1989-02-08	1989-02-08	2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
CA002152269A CA2152269C (en)	1989-02-08	1992-12-21	Process for preparing substituted 1,3-oxathiolanes with antiviral properties

Publications (2)

Publication Number	Publication Date
AP9000163A0 AP9000163A0 (en)	1990-04-30
AP136A true AP136A (en)	1991-08-05

Family

ID=25678044

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
APAP/P/1990/000163A AP136A (en)	1989-02-08	1990-02-08	Substituted:- 1,3-oxathiolanes with antiviral properties.

Country Status (35)

Country	Link
US (1)	US5047407A (de)
EP (2)	EP0711771B1 (de)
JP (4)	JP2644357B2 (de)
KR (1)	KR960007531B1 (de)
CN (1)	CN1033640C (de)
AP (1)	AP136A (de)
AT (2)	ATE254125T1 (de)
AU (1)	AU630913B2 (de)
CA (1)	CA2009637C (de)
CY (1)	CY2036A (de)
CZ (1)	CZ282720B6 (de)
DE (3)	DE69034119T2 (de)
DK (2)	DK0711771T3 (de)
ES (2)	ES2206476T3 (de)
FI (1)	FI98065C (de)
GR (1)	GR3019919T3 (de)
HK (1)	HK51997A (de)
HR (1)	HRP940040B1 (de)
HU (2)	HU208134B (de)
IE (1)	IE72184B1 (de)
IL (1)	IL93318A (de)
LU (1)	LU88809I2 (de)
MX (1)	MX19437A (de)
NL (1)	NL960025I2 (de)
NO (2)	NO179518C (de)
NZ (1)	NZ232421A (de)
OA (1)	OA09193A (de)
PL (1)	PL164785B1 (de)
PT (1)	PT93094B (de)
RU (1)	RU2092485C1 (de)
SG (2)	SG77215A1 (de)
SI (1)	SI9010243B (de)
SK (1)	SK279175B6 (de)
YU (1)	YU48840B (de)
ZA (1)	ZA90943B (de)

Families Citing this family (151)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7119202B1 (en)	1989-02-08	2006-10-10	Glaxo Wellcome Inc.	Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties
US5270315A (en) *	1988-04-11	1993-12-14	Biochem Pharma Inc.	4-(purinyl bases)-substituted-1,3-dioxlanes
US6350753B1 (en)	1988-04-11	2002-02-26	Biochem Pharma Inc.	2-Substituted-4-substituted-1,3-dioxolanes and use thereof
US5466806A (en) *	1989-02-08	1995-11-14	Biochem Pharma Inc.	Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US6175008B1 (en)	1988-04-11	2001-01-16	Biochem Pharma Inc.	Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US6903224B2 (en)	1988-04-11	2005-06-07	Biochem Pharma Inc.	Substituted 1,3-oxathiolanes
US5047407A (en)	1989-02-08	1991-09-10	Iaf Biochem International, Inc.	2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
HU226137B1 (en) *	1989-02-08	2008-05-28	Shire Canada Inc	Process for preparing substituted 1,3-oxathiolanes with antiviral properties
UA45942A (uk) *	1989-02-08	2002-05-15	Біокем Фарма, Інк.	1,3-оксатіолан, його похідні, спосіб (варіанти) його одержання та фармацевтична композиція
US5700937A (en) *	1990-02-01	1997-12-23	Emory University	Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
US5276151A (en) *	1990-02-01	1994-01-04	Emory University	Method of synthesis of 1,3-dioxolane nucleosides
US5914331A (en) *	1990-02-01	1999-06-22	Emory University	Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5827727A (en) *	1990-02-01	1998-10-27	Emory University	Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US5204466A (en) *	1990-02-01	1993-04-20	Emory University	Method and compositions for the synthesis of bch-189 and related compounds
US6703396B1 (en)	1990-02-01	2004-03-09	Emory University	Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
GB9009861D0 (en)	1990-05-02	1990-06-27	Glaxo Group Ltd	Chemical compounds
US5587480A (en) *	1990-11-13	1996-12-24	Biochem Pharma, Inc.	Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties
US6369066B1 (en)	1990-11-13	2002-04-09	Biochem Pharma, Inc.	Substituted 1,3-oxathiolanes with antiviral properties
JP2960164B2 (ja) *	1990-11-13	1999-10-06	バイオケムファーマインコーポレイテッド	抗ウイルス特性を有する置換１，３−オキサチオラン類および置換１，３−ジチオラン類
US6228860B1 (en)	1990-11-13	2001-05-08	Biochem Pharma Inc.	Substituted 1,3-oxathiolanes with antiviral properties
US5925643A (en) *	1990-12-05	1999-07-20	Emory University	Enantiomerically pure β-D-dioxolane-nucleosides
US5248776A (en) *	1990-12-05	1993-09-28	University Of Georgia Research Foundation, Inc.	Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides
US5444063A (en) *	1990-12-05	1995-08-22	Emory University	Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5179104A (en) *	1990-12-05	1993-01-12	University Of Georgia Research Foundation, Inc.	Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
WO1992010496A1 (en) *	1990-12-05	1992-06-25	University Of Georgia Research Foundation, Inc.	ENANTIOMERICALLY PURE β-L-(-)-1,3-OXATHIOLANE NUCLEOSIDES
IL100502A (en) *	1991-01-03	1995-12-08	Iaf Biochem Int	PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
IL100965A (en) *	1991-02-22	1999-12-31	Univ Emory	2-Hydroxymethyl-5-(5-fluorocytosin-l-yl)-1,3-oxathiolane its resolution and pharmaceutical compositions containing it
RU2116789C1 (ru) *	1991-03-06	1998-08-10	Дзе Велкам Фаундейшн Лимитед	Способ ингибирования вирусных инфекций гепатита в
GB9104740D0 (en) *	1991-03-06	1991-04-17	Wellcome Found	Antiviral nucleoside combination
US6812233B1 (en) *	1991-03-06	2004-11-02	Emory University	Therapeutic nucleosides
WO1992018517A1 (en) *	1991-04-17	1992-10-29	Yale University	Method of treating or preventing hepatitis b virus
US5817667A (en) *	1991-04-17	1998-10-06	University Of Georgia Research Foudation	Compounds and methods for the treatment of cancer
GB9109506D0 (en) *	1991-05-02	1991-06-26	Wellcome Found	Therapeutic nucleosides
DK0513917T4 (da) *	1991-05-16	2001-06-25	Glaxo Group Ltd	Antivirale kombinationer indeholdende nukleosidanaloger
GB9110624D0 (en) *	1991-05-16	1991-07-03	Glaxo Group Ltd	Combinations
GB9110874D0 (en) *	1991-05-20	1991-07-10	Iaf Biochem Int	Medicaments
ZA923640B (en) *	1991-05-21	1993-02-24	Iaf Biochem Int	Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) *	1991-06-03	1991-07-24	Glaxo Group Ltd	Chemical compounds
GB9116601D0 (en) *	1991-08-01	1991-09-18	Iaf Biochem Int	1,3-oxathiolane nucleoside analogues
EP0530407B1 (de) *	1991-09-04	1996-06-05	Stichting REGA V.Z.W.	Substituierte Nukleosidderivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zusammensetzungen
US20050192299A1 (en) *	1992-04-16	2005-09-01	Yung-Chi Cheng	Method of treating or preventing hepatitis B virus
ATE184787T1 (de) *	1992-05-13	1999-10-15	Wellcome Found	Therapeutische kombinationen
US6177435B1 (en)	1992-05-13	2001-01-23	Glaxo Wellcome Inc.	Therapeutic combinations
US6444656B1 (en)	1992-12-23	2002-09-03	Biochem Pharma, Inc.	Antiviral phosphonate nucleotides
US6005107A (en)	1992-12-23	1999-12-21	Biochem Pharma, Inc.	Antiviral compounds
GB9226879D0 (en) *	1992-12-23	1993-02-17	Iaf Biochem Int	Anti-viral compounds
GB9311709D0 (en) *	1993-06-07	1993-07-21	Iaf Biochem Int	Stereoselective synthesis of nucleoside analogues using bicycle intermediate
WO1995007086A1 (en) *	1993-09-10	1995-03-16	Emory University	Nucleosides with anti-hepatitis b virus activity
US20020120130A1 (en) *	1993-09-10	2002-08-29	Gilles Gosselin	2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
US5587362A (en) *	1994-01-28	1996-12-24	Univ. Of Ga Research Foundation	L-nucleosides
IL113432A (en) *	1994-04-23	2000-11-21	Glaxo Group Ltd	Process for the diastereoselective synthesis of nucleoside analogues
FR2720397B1 (fr) *	1994-05-24	1996-08-23	Laphal Laboratoires Sa	Nouveaux oxathiolanes, leur procédé de préparation et les compositions pharmaceutiques qui en renferment.
IL115156A (en) *	1994-09-06	2000-07-16	Univ Georgia	Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5968910A (en) *	1994-11-30	1999-10-19	Jan M. R. Balzarini	Compositions containing two or three inhibitors of different HIV reverse transcriptases
US6391859B1 (en)	1995-01-27	2002-05-21	Emory University	[5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5703058A (en) *	1995-01-27	1997-12-30	Emory University	Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5808040A (en) *	1995-01-30	1998-09-15	Yale University	L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
MY115461A (en)	1995-03-30	2003-06-30	Wellcome Found	Synergistic combinations of zidovudine, 1592u89 and 3tc
WO1996031217A1 (en) *	1995-04-04	1996-10-10	Duke University	Inhibiting retroviral replication
DK0831852T3 (da) *	1995-06-07	2007-03-19	Univ Emory	Nukleosider med anti-hepatitis B-virusaktivitet
GB9605293D0 (en) *	1996-03-13	1996-05-15	Glaxo Group Ltd	Medicaments
FR2746396B1 (fr) *	1996-03-20	1998-06-05	Inst Nat Sante Rech Med	1,3-thiazolidin-4-ones et 1,3-thiazolidines substituees, procede d'obtention de ces composes et leurs utilisations comme medicaments
JP2000515852A (ja)	1996-06-25	2000-11-28	グラクソ、グループ、リミテッド	Ｈｉｖの治療に使用するためのｖｘ４７８、ジドブジン、ｆｔｃおよび／または３ｔｃを含んでなる組合わせ
US5753789A (en) *	1996-07-26	1998-05-19	Yale University	Oligonucleotides containing L-nucleosides
US6113920A (en) *	1996-10-31	2000-09-05	Glaxo Wellcome Inc.	Pharmaceutical compositions
US6022876A (en) *	1996-11-15	2000-02-08	Yale University	L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
US5792773A (en) *	1996-11-15	1998-08-11	Yale University	L-β-dioxolane uridine analog administration for treating Epstein-Barr virus infection
US20040044016A1 (en) *	1997-01-31	2004-03-04	Mitsubishi Chemical Corporation	Antiviral agents
DE69823984T2 (de) *	1997-03-19	2005-05-12	University Of Georgia Research Foundation, Inc.	Synthese, anti-hiv- und anti-hepatitis-b-virus-aktivitäten von 1,3-oxaselenolannukleosiden
TW536403B (en) *	1997-03-24	2003-06-11	Glaxo Group Ltd	An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
IT1290447B1 (it)	1997-03-28	1998-12-03	Zambon Spa	Derivati 1,3-ossatiolanici ad attivita' antivirale
JP2001518899A (ja)	1997-04-07	2001-10-16	トライアングルファーマシューティカルズ，インコーポレイティド	他の抗ウイルス剤との組合せにおけるｍｋｃ−４４２の使用
AU2787199A (en)	1998-02-25	1999-09-15	Emory University	2'-fluoronucleosides
EP1754710A3 (de)	1998-02-25	2007-12-19	Emory University	2'-Fluoronukleoside
EP1104415B1 (de)	1998-08-12	2004-11-10	Gilead Sciences, Inc.	Verfahren zur herstellung von 1,3-oxathiolannukleoside
US6979561B1 (en) *	1998-10-09	2005-12-27	Gilead Sciences, Inc.	Non-homogeneous systems for the resolution of enantiomeric mixtures
ES2237189T3 (es)	1998-11-02	2005-07-16	Gilead Sciences, Inc.	Terapia de combinacion para tratar virus de la hepatitis b.
EP1124839B1 (de)	1998-11-05	2006-01-11	Centre National De La Recherche Scientifique (Cnrs)	Nukleoside mit anti-hepatitis b virus wirkung
EA004767B1 (ru)	1998-12-23	2004-08-26	Шайре Байокем Инк.	Аналоги нуклеозида (варианты) и их применение, комбинация и способ лечения вирусных инфекций, фармацевтическая композиция
DK1165096T3 (da) *	1999-03-29	2010-01-25	Shire Canada Inc	Anvendelse af cytidinderivater til behandling af leukæmi
EP1180104B1 (de)	1999-05-26	2003-03-26	Johnson Matthey Pharmaceutical Materials Inc	Verfahren zu trennung von ftc isomere und deren derivate
US6752929B1 (en) *	1999-05-26	2004-06-22	Johnson Matthey Pharmaceutical Materials, Inc.	Methods of separating FTC isomers and derivatives thereof
US6653318B1 (en)	1999-07-21	2003-11-25	Yale University	5-(E)-Bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use
US6432966B2 (en) *	1999-10-29	2002-08-13	Smithkline Beecham Corporation	Antiviral combinations
EP1600452A3 (de)	1999-11-12	2008-09-10	Pharmasset, Inc.	Herstellung von 2'-Deoxy-L-Nukleoside
KR100789162B1 (ko) *	1999-11-12	2007-12-28	파마셋 인코포레이티드	2'-데옥시-ｌ-뉴클레오사이드의 합성
US6436948B1 (en)	2000-03-03	2002-08-20	University Of Georgia Research Foundation Inc.	Method for the treatment of psoriasis and genital warts
GB0016845D0 (en) *	2000-07-07	2000-08-30	Leuven K U Res & Dev	Pharmaceutical composition for treatment of HIV infection
WO2002051852A1 (fr) *	2000-12-27	2002-07-04	Mitsui Chemicals, Inc.	Procede de production d'un derive de saccharide non naturel
CN1503796B (zh)	2001-03-01	2012-07-04	三角药品公司	顺-ftc的多晶型物及其它晶型
US6600044B2 (en)	2001-06-18	2003-07-29	Brantford Chemicals Inc.	Process for recovery of the desired cis-1,3-oxathiolane nucleosides from their undesired trans-isomers
JP2003039582A (ja) *	2001-07-19	2003-02-13	Three M Innovative Properties Co	湿潤防滑性シート及び湿潤防滑構造体
MY169670A (en)	2003-09-03	2019-05-08	Tibotec Pharm Ltd	Combinations of a pyrimidine containing nnrti with rt inhibitors
US6855346B2 (en) *	2001-10-05	2005-02-15	Tzu-Sheng Wu	Pharmaceutical composition having prophylactic effects on lamivudine-related disease relapse and drug resistance and methods of using the same
HU230248B1 (hu) *	2001-10-26	2015-11-30	Msd Italia S.R.L.	N-szubsztituált hidroxipirimidinon-karboxamid HIV-integráz inhibitorok
US20030162992A1 (en) *	2001-12-14	2003-08-28	Watanabe Kyoichi A.	Preparation of intermediates useful in the synthesis of antiviral nucleosides
IL163666A0 (en)	2002-02-22	2005-12-18	New River Pharmaceuticals Inc	Active agent delivery systems and methods for protecting and administering active agents
EP1534255B1 (de)	2002-08-06	2011-01-19	Pharmasset, Inc.	Verfahren zur herstellung von 1,3-dioxolan-nucleosiden
DE10238723A1 (de) *	2002-08-23	2004-03-11	Bayer Ag	Phenyl-substituierte Pyrazolyprimidine
DE10238724A1 (de)	2002-08-23	2004-03-04	Bayer Ag	Alkyl-substituierte Pyrazolpyrimidine
DE10238722A1 (de) *	2002-08-23	2004-03-11	Bayer Ag	Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
JP2006508134A (ja) *	2002-11-08	2006-03-09	グラクソ　グループ　リミテッド	医薬組成物
CA2502625A1 (en)	2002-12-09	2004-06-24	The University Of Georgia Research Foundation, Inc.	Dioxolane thymine and combinations for use against resistant strains of hiv
SI1583542T1 (sl) *	2003-01-14	2008-12-31	Gilead Sciences Inc	Sestavki in postopki za kombinacijsko antivirusnoterapijo
US8044060B2 (en)	2003-05-09	2011-10-25	Boehringer Ingelheim International Gmbh	6-cyclylmethyl- and 6-alkylmethyl pyrazolo[3,4-D]pyrimidines, methods for their preparation and methods for their use to treat impairments of perception, concentration learning and/or memory
DE10320785A1 (de) *	2003-05-09	2004-11-25	Bayer Healthcare Ag	6-Arylmethyl-substituierte Pyrazolopyrimidine
DE102004001873A1 (de) *	2004-01-14	2005-09-29	Bayer Healthcare Ag	Cyanopyrimidinone
PL216369B1 (pl)	2004-07-27	2014-03-31	Gilead Sciences	Pochodne fosfonianowe, kompozycje farmaceutyczne zawierające te pochodne oraz zastosowanie tych pochodnych do wytwarzania leku do hamowania wirusa HIV
JP2006214695A (ja) *	2005-02-07	2006-08-17	Sanken Setsubi Kogyo Co Ltd	空調システム
TWI471145B (zh) *	2005-06-13	2015-02-01	Bristol Myers Squibb & Gilead Sciences Llc	單一式藥學劑量型
TWI375560B (en) *	2005-06-13	2012-11-01	Gilead Sciences Inc	Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
US20070059360A1 (en) *	2005-07-29	2007-03-15	Ashish Jaiswal	Water-dispersible anti-retroviral pharmaceutical compositions
KR20080053317A (ko) *	2005-08-31	2008-06-12	씨아이피엘에이 엘티디.	라미부딘, 스타부딘 및 네비라핀을 포함하는 약학적 조합물
CN1328240C (zh) *	2005-08-31	2007-07-25	四川大学	苯甲酰氧基乙醛的制备方法
CA2623522C (en) *	2005-09-26	2015-12-08	Pharmasset, Inc.	Modified 4'-nucleosides as antiviral agents
US20080317852A1 (en) *	2005-12-14	2008-12-25	Amar Lulla	Pharmaceutical Combination
US8895531B2 (en) *	2006-03-23	2014-11-25	Rfs Pharma Llc	2′-fluoronucleoside phosphonates as antiviral agents
CA2649796A1 (en) *	2006-04-18	2007-10-25	Lupin Limited	A novel crystalline form of lamivudine
WO2008053496A2 (en) *	2006-10-30	2008-05-08	Lupin Limited	An improved process for the manufacture of cis (-)-lamivudine
KR100840495B1 (ko)	2007-04-13	2008-06-23	한미약품 주식회사	라미부딘을 입체선택적으로 제조하는 방법
USRE45004E1 (en)	2007-06-18	2014-07-08	Sunshine Lake Pharma Co., Ltd.	Bromo-phenyl substituted thiazolyl dihydropyrimidines
US20100190982A1 (en) *	2007-09-17	2010-07-29	Janardhana Rao Vascuri	Process for the preparation of lamivudine form i
BRPI0820224A2 (pt) *	2007-11-29	2015-06-16	Ranbaxy Lab Ltd	Composto de fórmula iii ou seus estereoisômeros; processo para sua preparação e seu uso; uso de um composto de formula iii(a) ou iii(b) em um processo para a preparação de lamivudina de fórmula i(a) ou um composto de fórmula i(c); processo para preparação de lamivudina de fórmula i(a)
SI2225232T1 (sl) *	2007-11-29	2012-12-31	Ranbaxy Laboratories Limited	Postopek za pripravo substituiranih 1,3-oksatiolanov
EP2217602B1 (de) *	2007-11-30	2018-08-29	Boehringer Ingelheim International GmbH	1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-on- derivative und ihre verwendung als pde9a modulatoren zur behandlung von erkrankungen des zns
UA105362C2 (en)	2008-04-02	2014-05-12	Бьорингер Ингельхайм Интернациональ Гмбх	1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
TW201010692A (en)	2008-06-19	2010-03-16	Public Univ Corp Nagoya City Univ	Pharmaceutical composition for treatment or prevention of hbv infection
PE20110383A1 (es)	2008-09-08	2011-07-15	Boehringer Ingelheim Int	Pirazolopirimidinonas como inhibidores de la fosfodiesterasa 9a (pde9a)
WO2010077613A1 (en)	2008-12-09	2010-07-08	Gilead Sciences, Inc.	Modulators of toll-like receptors
WO2010082128A1 (en)	2009-01-19	2010-07-22	Aurobindo Pharma Limited	Process for the preparation of cis-nucleoside derivative
CA2757231A1 (en) *	2009-03-31	2010-10-07	Boehringer Ingelheim International Gmbh	1-heterocyclyl-1,5-dihydro-pyrazolo [3,4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
KR101474570B1 (ko)	2009-04-13	2014-12-19	주식회사 대희화학	라미부딘의 신규한 중간체 및 이의 제조방법
AR077859A1 (es) *	2009-08-12	2011-09-28	Boehringer Ingelheim Int	Compuestos para el tratamiento de trastornos del snc
WO2011045815A2 (en)	2009-10-14	2011-04-21	Matrix Laboratories Ltd.	Process for the preparation of lamivudine and novel salts in the manufacture thereof
RS54123B1 (sr)	2010-01-27	2015-12-31	Viiv Healthcare Company	Terapeutska kombinacija koja sadrži dolutegravir, abacavir i lamivudine
US20120295930A1 (en)	2010-02-03	2012-11-22	Shankar Rama	Novel process for the preparation of cis-nucleoside derivative
US20110223131A1 (en)	2010-02-24	2011-09-15	Gilead Sciences, Inc.	Antiviral compounds
CN102234269B (zh) *	2010-04-29	2015-09-16	重庆医药工业研究院有限责任公司	拉米夫定的工业化制备方法
WO2011141805A2 (en)	2010-05-14	2011-11-17	Lupin Limited	An improved process for the manufacture of lamivudine
CN114010776A (zh)	2010-06-09	2022-02-08	疫苗技术股份有限公司	用于增强抗逆转录病毒治疗的hiv感染者的治疗性免疫
CA2807687C (en)	2010-08-12	2019-01-08	Boehringer Ingelheim International Gmbh	6-cycloalkyl-1, 5-dihydro-pyrazolo [3,4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors
US8809345B2 (en)	2011-02-15	2014-08-19	Boehringer Ingelheim International Gmbh	6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
EP2739620A1 (de)	2011-08-05	2014-06-11	Lupin Limited	Stereoselektives verfahren zur herstellung von 1,3-oxathiolan-nukleosiden
WO2013168066A1 (en)	2012-05-05	2013-11-14	Lupin Limited	An improved process for the manufacture of lamivudine form i.
CN103694231A (zh) *	2013-11-28	2014-04-02	安徽一帆香料有限公司	一种拉米夫定中间体hdms的合成制备方法
WO2016001907A1 (en)	2014-07-02	2016-01-07	Prendergast Patrick T	Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
EP4140485A1 (de)	2014-07-11	2023-03-01	Gilead Sciences, Inc.	Modulatoren von toll-like-rezeptoren zur behandlung von hiv
US9675632B2 (en)	2014-08-26	2017-06-13	Enanta Pharmaceuticals, Inc.	Nucleoside and nucleotide derivatives
HK1257270A1 (zh)	2015-09-15	2019-10-18	Gilead Sciences, Inc.	用於治療hiv的toll樣受體(tlr)調節劑
RU2736941C2 (ru)	2015-12-02	2020-11-23	Мерк Шарп энд Доум Корп.	Фармацевтические композиции, содержащие доравирин, тенофовира дизопроксила фумарат и ламивудин
EP3601301A1 (de)	2017-03-31	2020-02-05	The University of Liverpool	Prodrug-zusammensetzungen

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0131793A2 (de) *	1983-07-08	1985-01-23	Bayer Ag	5-Aminomethyl-1,3-oxathiolane

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4000137A (en) *	1975-06-10	1976-12-28	American Home Products Corporation	Antitumor derivatives of periodate-oxidized nucleosides
JPS5259171A (en) *	1975-11-10	1977-05-16	Asahi Chem Ind Co Ltd	Preparation of uracil derivatives
JPS6045196B2 (ja) *	1976-08-09	1985-10-08	株式会社興人	１−（２−テトラヒドロフリル）ウラシル類の製造方法
JPS5668674A (en) *	1979-11-08	1981-06-09	Shionogi & Co Ltd	5-fluorouracil derivative
JPS56167685A (en) *	1980-05-28	1981-12-23	Taiho Yakuhin Kogyo Kk	1- 2-tetrahydrothiophene-1,1-dioxide -5-fluorouracil and its preparation
JPS56169689A (en) *	1980-06-02	1981-12-26	Taiho Yakuhin Kogyo Kk	3-substituted-5-fluorouracil derivative and its preparation
JPS5738774A (en) *	1980-08-19	1982-03-03	Chugai Pharmaceut Co Ltd	Uracil derivative and its preparation
SU1035023A1 (ru) *	1982-03-23	1983-08-15	Ордена Трудового Красного Знамени Институт Органической И Физической Химии Им.А.Е.Арбузова	Способ получени 3-(тииранил-2-метил)-6-метилурацилов
NZ216172A (en) *	1985-05-15	1989-08-29	Wellcome Found	Nucleosides and pharmaceutical compositions
CA1294960C (en) *	1986-10-24	1992-01-28	Thomas C. Malone	7-deazaguanines as immunomodulators
DE3712735A1 (de) *	1987-04-15	1988-11-10	Boehringer Mannheim Gmbh	Neue pyrazolo(3,4-d)pyrimidine, verfahren zu ihrer herstellung und verwendung als arzneimittel
ES2075040T3 (es) *	1988-02-16	1995-10-01	Lilly Co Eli	2',3'-dideoxi-2',2'-difluoronucleosidos.
US5047407A (en) *	1989-02-08	1991-09-10	Iaf Biochem International, Inc.	2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
NZ228645A (en) *	1988-04-11	1991-09-25	Iaf Biochem Int	1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
US5204466A (en)	1990-02-01	1993-04-20	Emory University	Method and compositions for the synthesis of bch-189 and related compounds

1989
- 1989-02-08 US US07/308,101 patent/US5047407A/en not_active Expired - Lifetime
1990
- 1990-02-07 RU SU904743202A patent/RU2092485C1/ru active
- 1990-02-07 HU HU90708A patent/HU208134B/hu unknown
- 1990-02-08 SI SI9010243A patent/SI9010243B/sl unknown
- 1990-02-08 CN CN90100612A patent/CN1033640C/zh not_active Expired - Lifetime
- 1990-02-08 JP JP2031324A patent/JP2644357B2/ja not_active Expired - Lifetime
- 1990-02-08 SG SG1999000115A patent/SG77215A1/en unknown
- 1990-02-08 DE DE69034119T patent/DE69034119T2/de not_active Expired - Lifetime
- 1990-02-08 DK DK95120531T patent/DK0711771T3/da active
- 1990-02-08 EP EP95120531A patent/EP0711771B1/de not_active Expired - Lifetime
- 1990-02-08 ES ES95120531T patent/ES2206476T3/es not_active Expired - Lifetime
- 1990-02-08 AU AU49201/90A patent/AU630913B2/en not_active Expired
- 1990-02-08 LU LU88809C patent/LU88809I2/fr unknown
- 1990-02-08 ES ES90301335T patent/ES2086371T3/es not_active Expired - Lifetime
- 1990-02-08 ZA ZA90943A patent/ZA90943B/xx unknown
- 1990-02-08 NO NO900619A patent/NO179518C/no not_active IP Right Cessation
- 1990-02-08 YU YU24390A patent/YU48840B/sh unknown
- 1990-02-08 OA OA59735A patent/OA09193A/xx unknown
- 1990-02-08 PL PL90283692A patent/PL164785B1/pl unknown
- 1990-02-08 AT AT95120531T patent/ATE254125T1/de not_active IP Right Cessation
- 1990-02-08 PT PT93094A patent/PT93094B/pt active IP Right Grant
- 1990-02-08 KR KR1019900001493A patent/KR960007531B1/ko not_active Expired - Lifetime
- 1990-02-08 DE DE1996175032 patent/DE19675032I2/de active Active
- 1990-02-08 MX MX1943790A patent/MX19437A/es unknown
- 1990-02-08 CA CA002009637A patent/CA2009637C/en not_active Expired - Lifetime
- 1990-02-08 AT AT90301335T patent/ATE138065T1/de active
- 1990-02-08 IL IL9331890A patent/IL93318A/en not_active IP Right Cessation
- 1990-02-08 EP EP90301335A patent/EP0382526B1/de not_active Expired - Lifetime
- 1990-02-08 AP APAP/P/1990/000163A patent/AP136A/en active
- 1990-02-08 NZ NZ232421A patent/NZ232421A/xx unknown
- 1990-02-08 SG SG1996001044A patent/SG48737A1/en unknown
- 1990-02-08 IE IE45290A patent/IE72184B1/en not_active IP Right Cessation
- 1990-02-08 DK DK90301335.7T patent/DK0382526T3/da active
- 1990-02-08 FI FI900631A patent/FI98065C/fi active IP Right Grant
- 1990-02-08 DE DE69026971T patent/DE69026971T2/de not_active Expired - Lifetime
1991
- 1991-12-27 CZ CS914109A patent/CZ282720B6/cs not_active IP Right Cessation
- 1991-12-27 SK SK4109-91A patent/SK279175B6/sk unknown
1994
- 1994-01-24 HR HR940040A patent/HRP940040B1/xx not_active IP Right Cessation
- 1994-12-15 HU HU94P/P00058P patent/HU210537A9/hu unknown
1995
- 1995-08-16 JP JP07208936A patent/JP3105154B2/ja not_active Expired - Fee Related
1996
- 1996-05-16 GR GR960400767T patent/GR3019919T3/el unknown
- 1996-10-10 NL NL960025C patent/NL960025I2/nl unknown
1997
- 1997-04-24 HK HK51997A patent/HK51997A/en not_active IP Right Cessation
1998
- 1998-02-20 CY CY203698A patent/CY2036A/xx unknown
1999
- 1999-12-27 JP JP11370063A patent/JP2000143662A/ja active Pending
2001
- 2001-01-25 NO NO2001002C patent/NO2001002I1/no unknown
- 2001-03-05 JP JP2001059730A patent/JP2001226373A/ja active Pending

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0131793A2 (de) *	1983-07-08	1985-01-23	Bayer Ag	5-Aminomethyl-1,3-oxathiolane

Also Published As

Publication number	Publication date
EP0711771A2 (de)	1996-05-15
NO2001002I1 (no)	2001-02-12
EP0382526A2 (de)	1990-08-16
DE69034119T2 (de)	2004-08-26
US5047407A (en)	1991-09-10
JP2001226373A (ja)	2001-08-21
NO179518B (no)	1996-07-15
DE69034119D1 (de)	2003-12-18
CZ282720B6 (cs)	1997-09-17
FI900631A0 (fi)	1990-02-08
PT93094B (pt)	1995-12-29
MX19437A (es)	1993-05-01
NO179518C (no)	2000-09-11
CN1044817A (zh)	1990-08-22
HU208134B (en)	1993-08-30
ATE254125T1 (de)	2003-11-15
HRP940040B1 (en)	2002-04-30
SI9010243A (en)	1996-10-31
JPH037282A (ja)	1991-01-14
NO900619L (no)	1990-08-09
JPH08119967A (ja)	1996-05-14
ES2206476T3 (es)	2004-05-16
ZA90943B (en)	1990-10-31
NL960025I2 (nl)	1997-03-03
CY2036A (en)	1998-02-20
CS410991A3 (en)	1992-07-15
ATE138065T1 (de)	1996-06-15
HK1009270A1 (en)	1999-05-28
CA2009637A1 (en)	1990-08-08
FI98065B (fi)	1996-12-31
AU630913B2 (en)	1992-11-12
PT93094A (pt)	1990-08-31
JP2000143662A (ja)	2000-05-26
YU48840B (sh)	2002-06-19
HRP940040A2 (en)	1997-04-30
AU4920190A (en)	1990-08-16
NO900619D0 (no)	1990-02-08
DE69026971D1 (de)	1996-06-20
DK0711771T3 (da)	2004-03-22
EP0382526B1 (de)	1996-05-15
ES2086371T3 (es)	1996-07-01
HUT53362A (en)	1990-10-28
KR900012932A (ko)	1990-09-03
IE72184B1 (en)	1997-03-26
NL960025I1 (nl)	1997-01-06
LU88809I2 (fr)	1997-01-03
JP3105154B2 (ja)	2000-10-30
OA09193A (en)	1992-06-30
SK279175B6 (sk)	1998-07-08
YU24390A (en)	1991-10-31
IE960758L (en)	1990-08-08
DK0382526T3 (da)	1996-08-05
DE69026971T2 (de)	1996-09-12
HK51997A (en)	1997-05-02
SI9010243B (sl)	1998-08-31
AP9000163A0 (en)	1990-04-30
GR3019919T3 (en)	1996-08-31
IL93318A (en)	1995-07-31
HU210537A9 (en)	1995-04-28
SG77215A1 (en)	2000-12-19
HU900708D0 (en)	1990-04-28
RU2092485C1 (ru)	1997-10-10
DE19675032I2 (de)	2007-11-08
IE900452L (en)	1990-08-08
EP0711771A3 (de)	1996-07-10
FI98065C (fi)	1997-04-10
EP0711771B1 (de)	2003-11-12
EP0382526A3 (de)	1992-01-02
CN1033640C (zh)	1996-12-25
CA2009637C (en)	1997-10-07
JP2644357B2 (ja)	1997-08-25
PL164785B1 (en)	1994-10-31
SG48737A1 (en)	1998-05-18
NZ232421A (en)	1993-10-26
KR960007531B1 (ko)	1996-06-05

Publication	Publication Date	Title
AP136A (en)	1991-08-05	Substituted:- 1,3-oxathiolanes with antiviral properties.
US6350753B1 (en)	2002-02-26	2-Substituted-4-substituted-1,3-dioxolanes and use thereof
EP0560794B1 (de)	1996-09-18	Substituierte 1,3-oxathiolane mit antiviralen eigenschaften
US5538975A (en)	1996-07-23	1,3-oxathiolane nucleoside compounds and compositions
EP0756595B1 (de)	2002-03-06	Substituierte 1,3-oxathiolane mit antiviralen eigenschaften
US5151426A (en)	1992-09-29	2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US7122693B2 (en)	2006-10-17	Acetaldehyde acetal compounds, their synthesis, and uses thereof
US7119202B1 (en)	2006-10-10	Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties
HK1009270B (en)	2004-02-20	Substituted-1,3-oxathiolanes with antiviral properties
IE83856B1 (en)	2005-04-06	Substituted-1,3-oxathiolanes with antiviral properties
IE19960758A1 (en)	1990-08-08	Substituted-1,3-oxathiolanes with antiviral properties